"It is our job now to rigorously assess these data and the evidence
submitted on the vaccine’s safety, quality and effectiveness," said
June Raine, chief executive of Britain's Medicines and Healthcare
products Regulatory Agency.
"As we have received this data through a rolling review, we have
already started our analysis and will aim to make a decision in the
shortest time possible, without compromising the thoroughness of our
review."
(Reporting by Michael Holden; editing by Sarah Young)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |